JP2004533414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533414A5 JP2004533414A5 JP2002567285A JP2002567285A JP2004533414A5 JP 2004533414 A5 JP2004533414 A5 JP 2004533414A5 JP 2002567285 A JP2002567285 A JP 2002567285A JP 2002567285 A JP2002567285 A JP 2002567285A JP 2004533414 A5 JP2004533414 A5 JP 2004533414A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- delivery
- compound
- conjugate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 230000002708 enhancing effect Effects 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000005647 linker group Chemical group 0.000 claims description 25
- 235000009697 arginine Nutrition 0.000 claims description 21
- 239000004475 Arginine Substances 0.000 claims description 19
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 7
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 7
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004150 aciclovir Drugs 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229930105110 Cyclosporin A Natural products 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 229930028154 D-arginine Natural products 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 3
- 208000006550 Mydriasis Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010011033 Corneal oedema Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000001692 Esotropia Diseases 0.000 claims 1
- 208000018137 Extraocular muscle disease Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 206010026865 Mass Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000004931 Orbital Myositis Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 208000004350 Strabismus Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 206010044269 Toxocariasis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000001437 anti-cataract Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001713 cholinergic effect Effects 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 201000004778 corneal edema Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 201000000255 cycloplegia Diseases 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 201000010668 orbital plasma cell granuloma Diseases 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000001747 pupil Anatomy 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 101710149951 Protein Tat Proteins 0.000 description 43
- 108010043958 Peptoids Proteins 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 230000004700 cellular uptake Effects 0.000 description 26
- 239000000562 conjugate Substances 0.000 description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 229960003121 arginine Drugs 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 13
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 13
- 239000013543 active substance Substances 0.000 description 12
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 11
- 239000004471 Glycine Substances 0.000 description 11
- 229960002684 aminocaproic acid Drugs 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 10
- 229930012538 Paclitaxel Natural products 0.000 description 9
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 9
- 229960001592 paclitaxel Drugs 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 8
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- -1 α-chloroacetyl cyclosporin A derivatives Chemical class 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 229940000635 beta-alanine Drugs 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- YCEORMDTHWMXDU-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-( Chemical compound NC(N)=NCCCC(N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(O)=O YCEORMDTHWMXDU-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 101710192266 Tegument protein VP22 Proteins 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000003124 biologic agent Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000000863 peptide conjugate Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 2
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000015861 cell surface binding Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VCFCFPNRQDANPN-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NC(CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-UHFFFAOYSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical class C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229940021745 d- arginine Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 239000012026 peptide coupling reagents Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/792,480 US6669951B2 (en) | 1999-08-24 | 2001-02-23 | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| PCT/US2002/005804 WO2002067917A1 (en) | 2001-02-23 | 2002-02-25 | Compositions and methods for enhancing drug delivery across and into ocular tissues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004533414A JP2004533414A (ja) | 2004-11-04 |
| JP2004533414A5 true JP2004533414A5 (enExample) | 2006-01-05 |
Family
ID=25157022
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567285A Pending JP2004533414A (ja) | 2001-02-23 | 2002-02-25 | 眼組織を横切る薬物送達および眼組織内への薬物送達を増強するための組成物および方法 |
| JP2002569108A Pending JP2004530657A (ja) | 2001-02-23 | 2002-02-25 | 上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569108A Pending JP2004530657A (ja) | 2001-02-23 | 2002-02-25 | 上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US6669951B2 (enExample) |
| EP (2) | EP1367995A4 (enExample) |
| JP (2) | JP2004533414A (enExample) |
| CA (2) | CA2438326A1 (enExample) |
| MX (2) | MXPA03007590A (enExample) |
| WO (2) | WO2002069930A1 (enExample) |
Families Citing this family (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135191B2 (en) * | 1997-09-04 | 2006-11-14 | Zsolt Istvan Hertelendy | Urogenital or anorectal transmucosal vaccine delivery system |
| DE69930509T2 (de) * | 1998-07-08 | 2006-11-30 | Kirin-Amgen Inc., Wilmington | Pulverförmiges präparat zur anwendung auf schleimhäuten welches ein polymeres arzneimittel enthält |
| US20060025387A1 (en) * | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| US7214711B2 (en) * | 1998-12-23 | 2007-05-08 | Neurotherapeutics Pharma Llc | Method of treating migraine headache without aura |
| US8722668B2 (en) | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
| US8008283B2 (en) * | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| CA2797652C (en) * | 2000-07-21 | 2016-03-08 | Revance Therapeutics, Inc. | Multi-component biological transport systems |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| AU1482102A (en) * | 2000-11-14 | 2002-05-27 | Tocovite Pty Ltd | Complexes of phosphate derivatives |
| WO2002065986A2 (en) * | 2001-02-16 | 2002-08-29 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
| US20040156835A1 (en) * | 2001-05-30 | 2004-08-12 | Taiji Imoto | Protein preparation |
| MXPA04000654A (es) | 2001-07-27 | 2004-03-19 | Vital Health Sciences Pty Ltd | Terapia dermica usando derivados de fosfato de agente de transferencia de electrones. |
| MXPA04005611A (es) * | 2001-12-11 | 2005-04-19 | Cellgate Inc | Reactivos y conjugados de transporte de guanidinio. |
| CA2466536C (en) * | 2001-12-13 | 2012-02-07 | Vital Health Sciences Pty Ltd | Transdermal transport of compounds |
| AU2002359855B2 (en) | 2001-12-21 | 2008-08-21 | David S. Soane | Use of oligomers and polymers for drug solublization, stabilization, and delivery |
| FR2836474B1 (fr) * | 2002-02-22 | 2004-12-24 | Synt Em | Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique |
| WO2003090604A2 (en) * | 2002-04-24 | 2003-11-06 | University Of Florida | Method of endovascular brain mapping |
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| WO2004017904A2 (en) * | 2002-08-23 | 2004-03-04 | The Mclean Hospital Corporation | Corticosteroid conjugates and uses thereof |
| US7458982B2 (en) * | 2002-10-04 | 2008-12-02 | Photokinetix, Inc. | Photokinetic delivery of biologically active substances using pulsed incoherent light |
| US6969514B2 (en) * | 2003-02-05 | 2005-11-29 | Soll David B | Method for treating elevated intraocular pressure, including glaucoma |
| JP2006524232A (ja) * | 2003-03-17 | 2006-10-26 | アルバニー モレキュラー リサーチ インコーポレーティッド | 新規サイクロスポリン |
| US7332164B2 (en) * | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| EP2351844B1 (en) * | 2003-04-29 | 2014-06-11 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| ZA200509229B (en) * | 2003-05-01 | 2007-03-28 | Cornell Res Foundation Inc | Method and carrier complexes for delivering molecules to cells |
| EP1668145A4 (en) * | 2003-08-07 | 2010-03-10 | Avi Biopharma Inc | SENSE ANTIVIRUS COMPOUND AND METHOD FOR TREATING SSRNA VIRUS INFECTION |
| US20050136437A1 (en) * | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US20050203041A1 (en) * | 2003-09-23 | 2005-09-15 | Mourich Dan V. | Antisense compound and method for selectively killing activated T cells |
| US20050074506A1 (en) * | 2003-10-02 | 2005-04-07 | Brainsgate Ltd. | Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders |
| DE10355559A1 (de) * | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| US20060182692A1 (en) * | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| JP2007526316A (ja) * | 2004-03-01 | 2007-09-13 | ルーメン セラピューティックス リミテッド ライアビリティ カンパニー | 疾患を処置するための組成物および方法 |
| PT1729821E (pt) | 2004-03-03 | 2013-10-23 | Revance Therapeutics Inc | Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas |
| AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| DE602005025979D1 (de) * | 2004-03-03 | 2011-03-03 | Vital Health Sciences Pty Ltd | Alkaloid-formulierungen |
| EP1734991A4 (en) | 2004-04-14 | 2012-10-24 | Avirid Inc | COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| DK1768657T3 (da) | 2004-06-23 | 2008-12-01 | Sirion Therapeutics Inc | Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater |
| EP2269650A3 (en) * | 2004-08-03 | 2012-05-16 | Vital Health Sciences Pty Ltd. | Carrier for enteral administration |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| JP2008514701A (ja) * | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | シクロスポリンアルキン類似体およびそれらの薬学的使用 |
| US7511013B2 (en) * | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| WO2006041631A2 (en) * | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2006052860A2 (en) | 2004-11-04 | 2006-05-18 | Sirion Therapeutics, Inc. | Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation |
| EP1656951A1 (en) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
| US7603097B2 (en) | 2004-12-30 | 2009-10-13 | Valeo Radar Systems, Inc. | Vehicle radar sensor assembly |
| AU2006213686A1 (en) * | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| BRPI0608249A2 (pt) | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
| US8022179B2 (en) | 2005-03-03 | 2011-09-20 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
| US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
| CA2611831C (en) | 2005-06-17 | 2014-09-16 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2007030576A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| EP1924292A2 (en) * | 2005-09-16 | 2008-05-28 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| US7745392B2 (en) | 2005-09-23 | 2010-06-29 | Nitto Denko Corporation | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues |
| WO2007038172A2 (en) * | 2005-09-23 | 2007-04-05 | Nitto Denko Corporation | Guanidinium carriers |
| WO2007038171A2 (en) | 2005-09-23 | 2007-04-05 | Nitto Denko Corporation | Peptide nucleic acid based guanidinium compounds |
| CA2625918A1 (en) * | 2005-10-17 | 2007-04-26 | Neurotherapeutics Pharma, Inc. | Diuretic-like compound analogs useful for regulation of central nervous system disorders |
| US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| WO2007059528A2 (en) | 2005-11-17 | 2007-05-24 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
| US7740880B2 (en) | 2006-03-03 | 2010-06-22 | University Of Utah Research Foundation | Polymeric carrier for delivery of small interfering RNA |
| US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US20090311699A1 (en) * | 2006-09-25 | 2009-12-17 | Cmed Technologies Ltd. | Method of surface plasmon resonance (spr) to detect genomic aberrations in patients with chronic lymphocytic leukemia |
| BRPI0714762A2 (pt) * | 2006-09-27 | 2014-12-23 | Paolo Botti | Meios e métodos de aumento de entrega para sistemas biológicos |
| AU2006350707A1 (en) | 2006-11-08 | 2008-05-15 | Chongxi Yu | Transdermal delivery systems of peptides and related compounds |
| CN102988995A (zh) * | 2006-12-29 | 2013-03-27 | 雷文斯治疗公司 | 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法 |
| BRPI0720729A2 (pt) * | 2006-12-29 | 2014-04-08 | Revance Therapeutics Inc | Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa. |
| US8772471B2 (en) * | 2007-01-26 | 2014-07-08 | Industry-University Cooperation Foundation Hanyang University | Targeted delivery of siRNA |
| US20080200441A1 (en) * | 2007-02-14 | 2008-08-21 | University Of Southern California | Estrogen receptor modulators associated pharmaceutical compositions and methods of use |
| JP5864100B2 (ja) * | 2007-06-29 | 2016-02-17 | サレプタ セラピューティクス インコーポレイテッド | 組織特異的ペプチドコンジュゲートおよび方法 |
| AU2015200600B2 (en) * | 2007-06-29 | 2017-04-20 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| EP2178549B1 (en) | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
| AU2008295509A1 (en) * | 2007-08-29 | 2009-03-12 | Tufts University | Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| US20110160146A1 (en) * | 2008-02-07 | 2011-06-30 | National Institute of Health (NIH) | Conjungation of Small Molecules to Octaarginine Transporters for Overcoming Multi-Drug Resistance |
| EP2123262A1 (en) | 2008-05-20 | 2009-11-25 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| KR20160083953A (ko) * | 2008-09-23 | 2016-07-12 | 라보라토리 스킨 케어, 인크. | 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도 |
| WO2010080554A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| TWI568447B (zh) | 2009-05-08 | 2017-02-01 | 上海泰飛爾生化技術有限公司 | 具有快速透皮速度的多肽及多肽相關化合物的前藥組合物 |
| WO2010141845A2 (en) | 2009-06-05 | 2010-12-09 | 13Therapeutics, Inc. | Immunoregulatory peptides and methods of use |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2011060320A1 (en) | 2009-11-13 | 2011-05-19 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| AU2010321784B2 (en) * | 2009-11-23 | 2014-04-24 | Research Development Foundation | Recombinant filaggrin polypeptides for cell importation |
| AU2011213557B2 (en) | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| EP2552486B1 (en) | 2010-03-30 | 2020-08-12 | Phosphagenics Limited | Transdermal delivery patch |
| JP6066900B2 (ja) | 2010-04-26 | 2017-01-25 | エータイアー ファーマ， インコーポレイテッド | システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
| JP6008837B2 (ja) | 2010-04-28 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| US8986680B2 (en) | 2010-04-29 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
| WO2011139907A2 (en) | 2010-04-29 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
| AU2011248227B2 (en) | 2010-05-03 | 2016-12-01 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| JP6008841B2 (ja) | 2010-05-03 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
| EP2566499B1 (en) | 2010-05-04 | 2017-01-25 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
| EP2568996B1 (en) | 2010-05-14 | 2017-10-04 | aTyr Pharma, Inc. | Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| CN103096913B (zh) | 2010-05-27 | 2017-07-18 | Atyr 医药公司 | 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CA2800281C (en) | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| CA2804416C (en) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| JP5964304B2 (ja) | 2010-08-25 | 2016-08-03 | エータイアー ファーマ， インコーポレイテッド | チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| WO2012050673A1 (en) * | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
| CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
| US8580748B2 (en) | 2011-04-06 | 2013-11-12 | 13Therapeutics, Inc. | Peptides for the treatment of hearing |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| JP6336902B2 (ja) * | 2011-06-22 | 2018-06-06 | ビョーメ バイオサイエンシズ ピーブイティー．リミテッド | コンジュゲートベースの抗真菌性および抗菌性プロドラッグ |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| CN104540504A (zh) | 2012-01-18 | 2015-04-22 | 苏州泰飞尔医药有限公司 | 治疗肺部疾病的高穿透力前药组合物和医药组合物 |
| WO2013162729A1 (en) | 2012-04-24 | 2013-10-31 | The Board Of Trustees Of The Leland Stanford Junior University | Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters |
| US9782491B2 (en) | 2012-06-04 | 2017-10-10 | Indiana University Research And Technology Corporation | Peptide conjugates for treating pain |
| US9089536B2 (en) | 2012-06-06 | 2015-07-28 | Brian J. Smith | Ophthalmic solution for absorbing ultraviolet radiation and method for absorbing ultraviolet radiation |
| HK1212618A1 (zh) * | 2012-10-16 | 2016-06-17 | 恩多塞特公司 | 含有非天然氨基酸的藥物遞送綴合物以及其使用方法 |
| MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| MX2015016588A (es) * | 2013-06-11 | 2016-07-26 | Portage Pharmaceuticals Ltd | Estructura, fabricacion y usos de los peptidos permeables a las celulas, derivados de humanos, conjugados con los peptidos de carga especificos, biologicamente activos. |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| JP2016538327A (ja) | 2013-09-24 | 2016-12-08 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | デスモグレイン２（ｄｓｇ２）結合タンパク質およびその使用 |
| PL3149025T3 (pl) | 2014-05-21 | 2019-11-29 | Entrada Therapeutics Inc | Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania |
| US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| EP3185880B1 (en) | 2014-08-27 | 2020-02-12 | Ohio State Innovation Foundation | Improved peptidyl calcineurin inhibitors |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
| WO2018022930A1 (en) * | 2016-07-27 | 2018-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Immolative cell-penetrating complexes for nucleic acid delivery |
| MD3554553T2 (ro) | 2016-12-19 | 2022-10-31 | Sarepta Therapeutics Inc | Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară |
| KR102647670B1 (ko) | 2016-12-21 | 2024-03-15 | 아베초 바이오테크놀로지 리미티드 | 방법 |
| JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 |
| KR102093209B1 (ko) * | 2017-05-11 | 2020-03-25 | (주)케어젠 | 이소트레티노인과 펩타이드의 결합체 |
| JP2020534285A (ja) | 2017-09-15 | 2020-11-26 | アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 投与および処置の方法 |
| US11339192B2 (en) | 2017-10-04 | 2022-05-24 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitors |
| WO2019148194A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Peptidyl inhibitors of calcineurin-nfat interaction |
| EP3755351A4 (en) | 2018-02-22 | 2021-11-24 | Entrada Therapeutics, Inc. | COMPOSITIONS AND TREATMENT METHODS FOR MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY |
| JP2021107327A (ja) * | 2018-04-09 | 2021-07-29 | 国立研究開発法人産業技術総合研究所 | 生理活性を持つ中分子の薬物動態を改善する方法、薬物動態の改善を利用した中分子ライブラリの製造法 |
| EP3787671A4 (en) | 2018-05-04 | 2022-06-15 | Ohio State Innovation Foundation | NON-PEPTIDE CELL-PENETRATING MOTIFS |
| EP3790890A4 (en) | 2018-05-09 | 2022-03-02 | Ohio State Innovation Foundation | CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES |
| KR102167755B1 (ko) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| SI3678705T1 (sl) | 2018-09-14 | 2023-10-30 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | Konjugati montelukasta in peptidov |
| CN109010798A (zh) * | 2018-09-17 | 2018-12-18 | 中山大学中山眼科中心 | 一种多肽的新用途 |
| WO2020117429A1 (en) * | 2018-12-04 | 2020-06-11 | Purdue Research Foundation | Novel antibacterial cell-penetrating peptides |
| US20210346506A1 (en) * | 2020-05-07 | 2021-11-11 | Guibai Liang | Prodrug of itraconazole and uses thereof |
| WO2024100552A1 (en) * | 2022-11-08 | 2024-05-16 | Alcon Inc. | Prodrugs and compositions for ophthalmology applications |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE744988C (de) | 1941-02-01 | 1944-02-22 | Wilhelm Ulrich O | Handschraem- und Schlitzsaege |
| GB744988A (en) | 1952-01-31 | 1956-02-15 | Allen & Hanburys Ltd | Improvements in preparations of insulin |
| GB1541435A (en) | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
| US4847240A (en) | 1978-01-16 | 1989-07-11 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| DE2967069D1 (en) | 1978-01-16 | 1984-08-02 | Univ Boston | Effecting cellular uptake of molecules |
| US4701521A (en) | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4532207A (en) | 1982-03-19 | 1985-07-30 | G. D. Searle & Co. | Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase |
| US4880911A (en) | 1982-03-19 | 1989-11-14 | G. D. Searle & Co. | Fused polypeptides and methods for their detection |
| JPH0236570B2 (ja) | 1985-05-30 | 1990-08-17 | Toko Yakuhin Kogyo Kk | Shoenchintsunankozai |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5162505A (en) | 1989-09-19 | 1992-11-10 | Centocor | Proteins modified with positively charged carriers and compositions prepared therefrom |
| US5028707A (en) | 1989-11-20 | 1991-07-02 | Board Of Regents, University Of Texas | 4-hydroxyquinaldic acid derivatives |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| DK0506884T3 (da) | 1989-12-21 | 1996-11-04 | Whitehead Biomedical Inst | Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5674849A (en) | 1990-10-24 | 1997-10-07 | Allelix Biopharmaceuticals Inc. | Anti-viral compositions |
| US5646120A (en) | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
| US5831001A (en) | 1990-10-24 | 1998-11-03 | Allelix Biopharmaceuticals Inc. | Treatment of herpesvirus infection |
| ES2095959T3 (es) | 1990-10-24 | 1997-03-01 | Allelix Biopharma | Inhibidores de la replicacion del virus vih a base de peptidos. |
| US5633230A (en) | 1990-10-24 | 1997-05-27 | Allelix Biopharmaceuticals, Inc. | Treatment of cytomegalovirus infection |
| JPH07500820A (ja) | 1991-09-05 | 1995-01-26 | ユニバーシティ オブ コネティカット | ポリヌクレオチド又はオリゴヌクレオチドの細胞への標的を定めた送達 |
| DE69320469D1 (de) | 1992-04-23 | 1998-09-24 | Allelix Biopharma | Behandlung von herpesvirus infektion |
| CA2094658A1 (en) | 1992-04-23 | 1993-10-24 | Martin Sumner-Smith | Intracellular delivery of biochemical agents |
| GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| JP2702285B2 (ja) | 1992-08-21 | 1998-01-21 | バイオジェン，インコーポレイテッド | Ｔａｔ由来の輸送ポリペプチド |
| EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
| WO1994014464A1 (en) | 1992-12-22 | 1994-07-07 | Allelix Biopharmaceuticals Inc. | Synergistic compositions containing an antiviral nucleoside analogue and an antiviral oligopeptide |
| WO1995011038A1 (en) | 1993-10-22 | 1995-04-27 | Allelix Biopharmaceuticals Inc. | Treatment of cytomegalovirus infection |
| US6013628A (en) * | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5716614A (en) | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
| US5620013A (en) * | 1994-10-21 | 1997-04-15 | American Cyanamid Company | Method for destroying residual lens epithelial cells |
| US5783178A (en) | 1994-11-18 | 1998-07-21 | Supratek Pharma. Inc. | Polymer linked biological agents |
| AU4690596A (en) | 1994-12-30 | 1996-07-24 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
| AU735900B2 (en) | 1996-03-12 | 2001-07-19 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
| JP2000509394A (ja) | 1996-05-01 | 2000-07-25 | アンティバイラルズ インコーポレイテッド | 細胞膜を横切って物質を輸送するためのポリペプチド結合体 |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| JP3770666B2 (ja) | 1996-09-20 | 2006-04-26 | 株式会社ティ・ティ・エス技術研究所 | 経粘膜吸収製剤用組成物 |
| JPH10204000A (ja) | 1997-01-22 | 1998-08-04 | Nof Corp | 経皮吸収促進剤 |
| US6228344B1 (en) | 1997-03-13 | 2001-05-08 | Mallinckrodt Inc. | Method of measuring physiological function |
| AU734827B2 (en) | 1997-05-21 | 2001-06-21 | Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| US6730293B1 (en) * | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
| US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| MXPA02001857A (es) * | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
| US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| CA2797652C (en) | 2000-07-21 | 2016-03-08 | Revance Therapeutics, Inc. | Multi-component biological transport systems |
| WO2002065986A2 (en) * | 2001-02-16 | 2002-08-29 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
| US9810571B1 (en) | 2016-12-15 | 2017-11-07 | Chung-Hsiu Su | Hand truck with a loading weighing mechanism |
-
2001
- 2001-02-23 US US09/792,480 patent/US6669951B2/en not_active Expired - Fee Related
-
2002
- 2002-02-25 WO PCT/US2002/005829 patent/WO2002069930A1/en not_active Ceased
- 2002-02-25 EP EP02731103A patent/EP1367995A4/en not_active Ceased
- 2002-02-25 JP JP2002567285A patent/JP2004533414A/ja active Pending
- 2002-02-25 MX MXPA03007590A patent/MXPA03007590A/es active IP Right Grant
- 2002-02-25 JP JP2002569108A patent/JP2004530657A/ja active Pending
- 2002-02-25 CA CA002438326A patent/CA2438326A1/en not_active Abandoned
- 2002-02-25 CA CA002438784A patent/CA2438784A1/en not_active Abandoned
- 2002-02-25 WO PCT/US2002/005804 patent/WO2002067917A1/en not_active Ceased
- 2002-02-25 EP EP02713692A patent/EP1372626A4/en not_active Ceased
- 2002-02-25 MX MXPA03007591A patent/MXPA03007591A/es not_active Application Discontinuation
-
2003
- 2003-12-17 US US10/740,365 patent/US20040186045A1/en not_active Abandoned
-
2006
- 2006-10-02 US US11/542,278 patent/US20070173436A1/en not_active Abandoned
-
2010
- 2010-06-15 US US12/816,358 patent/US8623833B2/en not_active Expired - Fee Related
-
2013
- 2013-12-24 US US14/140,223 patent/US20140213532A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004533414A5 (enExample) | ||
| US8278264B2 (en) | Compositions and methods for enhancing drug delivery across and into ocular tissues | |
| EP1372626A1 (en) | Compositions and methods for enhancing drug delivery across and into ocular tissues | |
| AU2002306500B2 (en) | Transporters comprising spaced arginine moieties | |
| US6593292B1 (en) | Compositions and methods for enhancing drug delivery across and into epithelial tissues | |
| US8575305B2 (en) | Cell penetrating peptides | |
| US6730293B1 (en) | Compositions and methods for treating inflammatory diseases of the skin | |
| AU2013302270A1 (en) | Peptide-dendrimer conjugates and uses thereof | |
| AU2002306500A1 (en) | Transporters comprising spaced arginine moieties | |
| AU2002245529A1 (en) | Compositions and methods for enhancing drug delivery across and into ocular tissues | |
| AU2002303102A1 (en) | Compositions and methods for enhancing drug delivery across and into epithelial tissues |